Skip the wait and schedule your ER reservation in under 2 minutes. Text ‘ER Now‘ to (909) 298-1828 to begin.

ER Wait Time: 0 minutes | If you are having a medical emergency, call 9-1-1.
user-icon

Alzheimer’s Disease: Advancements on the Horizon

November marks Alzheimer’s Awareness Month, and is a great time to learn more about this devastating disease and explore the latest advances in research.

Alzheimer’s disease is a neurodegenerative disorder that causes progressive loss of memory, cognition, and behavior. It stands as the predominant cause of dementia, affecting over 6 million people in the United States.

While there is no definitive cure for Alzheimer’s disease, there are treatments that can help to slow the progression of the disease and alleviate symptoms. Researchers are also working on new and innovative treatments that could one day reverse or halt the disease entirely.

What Lies Ahead in Alzheimer’s Research?

One of the most promising breakthroughs in Alzheimer’s research is the approval of disease-modifying therapies (DMTs). These innovative drugs aim to tackle the disease at its roots by clearing amyloid plaques and tau tangles from the brain.

Amyloid plaques, composed of amyloid beta protein, and tau tangles, intricate protein fibers, are hallmark indicators of Alzheimer’s. They wreak havoc by causing harm and death to brain cells, ultimately leading to the manifestation of Alzheimer’s symptoms.

The FDA has granted approval to two DMTs for Alzheimer’s treatment: aducanumab (Aduhelm) and lecanemab (Leqembi). These drugs, known as monoclonal antibodies, are engineered proteins designed to target amyloid beta.

Both aducanumab and lecanemab have been shown to reduce amyloid plaques in the brain, but their ability to slow cognitive decline varies among patients. Some trials have shown a modest benefit, while others have shown no significant impact.

More research is needed to determine the long-term efficacy of these drugs and to identify the patients who are most likely to benefit from them. However, the approval of aducanumab and lecanemab represents a significant breakthrough in Alzheimer’s research, offering hope to patients and their families.

Other Promising Areas of Research

In addition to DMTs, researchers are also exploring other ways to treat and prevent Alzheimer’s disease. Some of the most promising areas of research include:

  1. Lifestyle interventions: Studies have shown that certain lifestyle factors, such as diet, exercise, and sleep, can help protect the brain from Alzheimer’s disease. Researchers are now working to develop evidence-based lifestyle interventions that can be used to prevent or slow the progression of the disease.
  2. Precision medicine: Scientists are harnessing genetic data and other relevant information to pinpoint distinct subtypes of Alzheimer’s. This information could be used to develop personalized treatments that cater to individual patient’s needs.
  3. Novel therapies: Researchers are exploring cutting-edge therapies, including stem cell treatments, gene editing, and immunotherapy. While these therapies are still in early stages of development, they have the potential to revolutionize the treatment of Alzheimer’s disease.

Dedicated Support for Alzheimer’s Patients and Their Families

There is no cure for Alzheimer’s disease, but there are treatments that can help to slow the progression of the disease and manage the symptoms. Researchers are also working on new and innovative treatments that could one day reverse or halt the disease entirely.

If you or someone you know has Alzheimer’s disease, it is important to talk to your doctor about the latest treatment options. There are many resources available to help you and your family cope with the disease.

For those affected by Alzheimer’s, reaching out for assistance is crucial. Montclair Hospital Medical Center is committed to providing top-tier care to Alzheimer’s patients and their families.

For more information on our Alzheimer’s treatment program and to schedule an appointment, please call 909-625-5411.